Skip to content
OpenCapital
Get started

Ardelyx ARDX IBSRELA — Total revenues

Other product segments

XPHOZAH
$23.3M-0.5%
Non-cash royalty revenue related to the sale of future royalties
$695K-32.3%
Product supply revenue
$354K+39.4%
Licensing revenue
$51K-99.0%

Similar metrics at other companies

Amgen logo
AMGNENBREL — Total revenues
$320M-37.3%
Incyte logo
INCYICLUSIG — Total revenues
$35.46M+20.0%
Organon logo
OGNInt’l — Revenue
$1.1B+0.1%
MetLife logo
METRIS — Total Revenues
$4.64B-0.1%
Pfizer logo
PFEIbrance — Revenues:
$1.01B+3.2%
Rhythm Pharmaceuticals, Inc. logo
RYTMSingle reportable segment — Total revenues
$60.11M+83.8%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%—
Net margin-13.6%—
FCF margin-40.9%—

Returns & leverage

See full
Return on equity-39.5%—
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's ibsrela — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's IBSRELA — total revenues?
Ardelyx (ARDX) reported IBSRELA — total revenues of $70.07M in Q1 2026.
How has Ardelyx's IBSRELA — total revenues changed year-over-year?
Ardelyx's IBSRELA — total revenues increased by 57.8% year-over-year, from $44.4M to $70.07M.
What does IBSRELA — total revenues mean?
This metric represents the total gross revenue generated from the commercial sales of a specific pharmaceutical product within the company's portfolio. It reflects the market adoption, pricing power, and demand for the therapeutic treatment among the target patient population. Tracking this revenue stream is essential for evaluating the commercial success and growth trajectory of the company's primary product launch.